# Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

> **NCT05392946** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 49 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Iberdomide

## Key facts

- **NCT ID:** NCT05392946
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-11
- **Primary completion:** 2026-09-29
- **Final completion:** 2028-09-29
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392946, "Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05392946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*